SCHEMBL16748427

SCHEMBL16748427

Cc1nc2c(F)cc(F)cc2n1-c1nc(N)nc(Nc2ccc(Cl)c(F)c2)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.38
AURKA O14965 1/20 0.37
AURKB Q96GD4 1/20 0.37
CYBB P04839 1/20 0.37
NOX5 Q96PH1 1/20 0.37
NOX3 Q9HBY0 1/20 0.37
NOX4 Q9NPH5 1/20 0.37
NOX1 Q9Y5S8 1/20 0.37
RAPGEF4 Q8WZA2 1/20 0.36
APP P05067 1/20 0.35
FFAR1 O14842 2/20 0.35
FFAR4 Q5NUL3 2/20 0.35
DHFR P00374 4/20 0.35
TDP1 Q9NUW8 1/20 0.35
HSP90AA1 P07900 1/20 0.35
MEN1 O00255 1/20 0.34
USP2 O75604 1/20 0.34
MAPT P10636 1/20 0.34
XBP1 P17861 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16748592 0.90 EGFR (0.41) MAPK1CYBBNOX5NOX3NOX4
SCHEMBL16748425 0.89 MAPK1 (0.36) MAPK1AURKAAURKBCYBBNOX5
SCHEMBL16748591 0.88 CYBB (0.44) MAPK1CYBBNOX5NOX3NOX4
SCHEMBL16748426 0.87 BMI1 (0.44) MAPK1AURKAAURKBCYBBNOX5
SCHEMBL16748436 0.86 AGPAT2 (0.42) MAPK1CYBBNOX5NOX3NOX4
SCHEMBL16748586 0.84 MAPT (0.44) MAPK1APPDHFRTDP1MEN1
SCHEMBL16740870 0.84 BMI1 (0.48) CYBBNOX5NOX3NOX4NOX1
SCHEMBL16748420 0.84 BMI1 (0.39) MAPK1CYBBNOX5NOX3NOX4
SCHEMBL16748419 0.84 PIK3CA (0.45) DHFRMEN1KMT2APIK3CDPIK3CA
SCHEMBL16740775 0.82 BMI1 (0.50) CYBBNOX5NOX3NOX4NOX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US claimed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US claimed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
WO-2015076801-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS BMI1, BAZ2A, BAZ2B MAPK1 1302/4885AURKA 4240/4885AURKB 3693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.